Coca-Cola FUZE purchase cleared
This article was originally published in The Tan Sheet
Executive Summary
Coca-Cola confirmed on March 2 FTC has approved its acquisition of FUZE Beverages without requiring any changes to the deal. The firm announced Feb. 1 its plan to purchase the FUZE Beverage line including lines Vitalize, Slenderize, Refresh and Tea (1"The Tan Sheet," Feb. 26, 2007, In Brief)...
You may also be interested in...
Food claim warning letter
Labeling for several FUZE Healthy Infuzions beverages stating vitamin B3 is "known to ... reduce cholesterol levels in blood" and polyphenols are "associated with reduced risk of developing cardiovascular disease and certain cancers" violates the Food, Drug & Cosmetic Act, FDA says in a recent 1warning letter to FUZE Beverages. These claims "promote [the] products for use as drugs." Additionally, the products "are labeled with a dietary supplement disclaimer statement," the agency adds. "Because these products are conventional foods, not dietary supplements, their labels should not include this disclaimer." The dietary supplement industry voiced its concerns to FDA at a recent meeting and asked that dietary supplements and functional foods be given a level "regulatory playing field" (2"The Tan Sheet" Dec. 11, 2006, p. 3). Coca-Cola announced Feb. 1 it intends to purchase FUZE to expand its beverage portfolio...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.